Drug reference
epalrestat
Aldose reductase inhibitor · Treatment for diabetic complications
Aldose reductase inhibitorTreatment for diabetic complications
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Epalrestat is an aldose reductase inhibitor. It works by delaying the accumulation of sorbitol in sciatic nerves and other tissues in diabetics. This mechanism is believed to be involved in the pathogenesis of diabetic neuropathy.
Indications
delay progression of diabetic neuropathy
Dosing
- Adult
- 50 mg three times daily (before meals)
Side effects
Common
nauseavomitingelevation of liver enzymes
Related guidelines
Ask House about epalrestat
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team